Xeris Biopharma Holdings (XERS) Cash from Investing Activities (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Cash from Investing Activities of -$325000.0 for Q1 2026, up 2.4% on a QoQ basis from -$333000.0 in Q4 2025, and down 2400.0% year-over-year from $14130.4 in Q1 2025.
Xeris Biopharma Holdings (XERS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$325000.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 2400.0% year-over-year to -$325000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 104.11% YoY) and the FY2025 annual result came in at -$696000.0, down 114.25% from the prior year.
- Cash from Investing Activities was -$325000.0 for Q1 2026 at Xeris Biopharma Holdings, up from -$333000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $14.9 million in Q4 2023 and bottomed at -$44.0 million in Q1 2023.
- A 5-year average of $1.9 million and a median of $6.7 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 118.44% — and 2026, when it slumped 2400.0%.
- Xeris Biopharma Holdings' Cash from Investing Activities stood at $9.2 million in 2022, then surged by 62.17% to $14.9 million in 2023, then slumped by 32.63% to $10.0 million in 2024, then sank by 103.32% to -$333000.0 in 2025, then increased by 2.4% to -$325000.0 in 2026.
- Business Quant data shows XERS's Cash from Investing Activities at -$325000.0 in Q1 2026, -$333000.0 in Q4 2025, and -$71000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.41 Bn | 1.30 Bn | 72.55 Mn | -325,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -325,000.00 |
| Mar 31, 2026 | -325,000.00 |
| Dec 31, 2025 | -333,000.00 |
| Dec 31, 2025 | -333,000.00 |
| Sep 30, 2025 | -71,000.00 |
| Sep 30, 2025 | -71,000.00 |
| Jun 30, 2025 | -279,000.00 |
| Jun 30, 2025 | -279,000.00 |
| Mar 31, 2025 | -13,000.00 |
| Mar 31, 2025 | -13,000.00 |
| Dec 31, 2024 | 10.02 Mn |
| Dec 31, 2024 | 10.02 Mn |
| Sep 30, 2024 | 9.91 Mn |
| Sep 30, 2024 | 9.91 Mn |
| Jun 30, 2024 | 4.60 Mn |
| Jun 30, 2024 | 4.60 Mn |
| Mar 31, 2024 | -19.65 Mn |
| Mar 31, 2024 | -19.65 Mn |
| Dec 31, 2023 | 14.87 Mn |
| Dec 31, 2023 | 14.87 Mn |